<DOC>
	<DOCNO>NCT02881853</DOCNO>
	<brief_summary>This Phase 1b , combine multiple dose subcutaneous ( SC ) bioavailability ( BA ) multiple ascend dose ( MAD ) study evaluate safety , tolerability BA SC XmAb7195 healthy subject subject atopic disease .</brief_summary>
	<brief_title>Safety , Tolerability , Bioavailability Subcutaneously Administered XmAb®7195</brief_title>
	<detailed_description>The study divide 2 part . Part A open-label , parallel group , BA study evaluate 4 once-weekly dos IV XmAb7195 SC XmAb7195 healthy subject . Each 5 treatment group consist 6 subject . Part B commence follow completion Part A randomized , double-blind , placebo-controlled , MAD study evaluate 4 weekly dos SC XmAb7195 healthy subject and/or subject atopic disease . Each treatment group consist 8 subject randomize 3:1 XmAb7195 : placebo Subjects part study follow least 28 day last dose .</detailed_description>
	<criteria>All Subjects : Male female 18 60 year age ( inclusive time screen ) . Total body weight 50.0 100.0 kg , body mass index ( BMI ) 19.0 35.0 kg/m2 ( inclusive , screen ) . Women either childbearing nonchildbearing potential . Must healthy clinically significant abnormality identify medical laboratory evaluation history clinically significant disorder , condition , disease would pose risk subject interfere study evaluation , procedure , completion assess Investigator . Subjects Atopic Disease Only ( Part B ) : Allergen skin test reactivity ≥ 5 mm wheal great saline control 2 follow 5 allergen : D. pteronyssinus , D. farina , ragweed , Virginia live oak , mountain cedar within 21 day prior dose . Sufficient clinical control subject 's atopic disease , opinion Investigator , subject unlikely require substantial change therapy medication duration trial unlikely require addition exclusionary medication Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , hematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue disease , disorder would pose significant risk subject 's safety significantly interfere study evaluation , procedure , completion assess Investigator . Subjects platelet count &lt; 150 k/uL screening time initial admission . Subjects peak expiratory flow rate &lt; 400 L/min male &lt; 350 L/min female . Subjects condition associate high risk bleeding : past history intracranial gastrointestinal bleeding , hemorrhagic condition include hereditary acquire bleeding , coagulation disorder . Subjects history clinically significant cardiovascular event : myocardial infarction , acute coronary syndrome , stroke , pulmonary embolism , and/or deep venous thrombosis . Subjects agree use medically acceptable method contraception ( define protocol ) . Subjects pregnant breast feeding , plan become pregnant within 30 day last dose XmAb7195 . Subjects use prescription drug within 28 day prior randomization follow exception Part B subject atopic disease : 1 . Intranasal corticosteroids allergic symptom dose stable 14 day prior randomization . 2 . Inhaled short act beta agonist ( SABA ) therapy bronchospasm dose stable 14 day prior randomization . 3 . No prescription drug allow unless agree clinically relevant Investigator Sponsor . Subjects asthma exacerbation require hospitalization within 1 year prior randomization require oral corticosteroid within 6 month prior randomization . Subjects poorly control asthma define SABA &gt; 6 times/day day within 4 week prior randomization . Subjects use follow medication within 3 month prior randomization : oral inhaled corticosteroid , long act beta agonist ( LABAs ) , leukotriene receptor antagonist ( LTRAs ) , asthma controller medication ( occasional SABA use allow ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>healthy</keyword>
	<keyword>atopic</keyword>
</DOC>